(VIANEWS) – EQUASENS (EQS.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| EQUASENS (EQS.PA) | €70.70 | 1.34% | 28.59% |
| TUBIZE-FIN (TUB.BR) | €78.30 | 1.12% | 9.88% |
| BIOMERIEUX (BIM.PA) | €98.06 | 0.88% | 12.93% |
| SARTORIUS STED BIO (DIM.PA) | €288.00 | 0.51% | 41.43% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. EQUASENS (EQS.PA)
1.34% Forward Dividend Yield and 28.59% Return On Equity
Equasens Société anonyme provides various IT solutions for the healthcare sector in Europe. It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker solutions for pharmacists' business processes; and solutions for energizing the customer relationship with pharmacists comprising OffiTag, OffiTouch, OffiMédia, OffiConnect, automation systems, and customer loyalty programs. The company also provides My Pilot, an analytics and management tool; OffiLearning, an e-learning tool; and solutions for patient support and advice, such as compliance monitoring software, Multimeds, Automeds, and OffiTéléconsult, as well as pharmaceutical record and shared medical record services. In addition, it offers a ULTIMATE, a system combining optimized pharmacy management and improved patient support; FARMACLICK, a protocol for communications between pharmacies and wholesalers-distributors; DIFARM, a solution for wholesalers-distributors; PHARE, a retail management tool; SOPHIA, a pharmacy management application; OffiMédia POS display; eNephro to enhance the care of chronic renal failure patients; and TPE Pilot, a web-based application that simplifies the management and sharing of patient education programs. Further, the company provides NOVIACARE; CARELIB Domicile; CARELIB EHPAD; KAPELSE solutions; TITAN solutions; ANTHADINE software and MOBISOINS mobile tool; MICROSOINS, an in-home nursing care solution; and LOGICLIC. Additionally, it offers AXIGATE solutions to manage the entire patient care pathway; CHORUS platform; medical telesecretarial services for healthcare professionals; and equipment lease financing solutions. The company was incorporated in 1996 and is based in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.59%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 30, 2022, the estimated forward annual dividend rate is 1.05 and the estimated forward annual dividend yield is 1.34%.
Yearly Top and Bottom Value
EQUASENS’s stock is valued at €70.70 at 07:30 EST, way under its 52-week high of €90.60 and way above its 52-week low of €57.80.
More news about EQUASENS.
2. TUBIZE-FIN (TUB.BR)
1.12% Forward Dividend Yield and 9.88% Return On Equity
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €1.92.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 13.38. Meaning, the purchaser of the share is investing €13.38 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.88%.
Moving Average
TUBIZE-FIN’s worth is higher than its 50-day moving average of €75.25 and higher than its 200-day moving average of €72.29.
Volume
Today’s last reported volume for TUBIZE-FIN is 8082 which is 16.43% above its average volume of 6941.
Yearly Top and Bottom Value
TUBIZE-FIN’s stock is valued at €78.30 at 07:30 EST, way under its 52-week high of €100.80 and way above its 52-week low of €65.40.
More news about TUBIZE-FIN.
3. BIOMERIEUX (BIM.PA)
0.88% Forward Dividend Yield and 12.93% Return On Equity
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Earnings Per Share
As for profitability, BIOMERIEUX has a trailing twelve months EPS of €3.86.
PE Ratio
BIOMERIEUX has a trailing twelve months price to earnings ratio of 28.76. Meaning, the purchaser of the share is investing €28.76 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.93%.
More news about BIOMERIEUX.
4. SARTORIUS STED BIO (DIM.PA)
0.51% Forward Dividend Yield and 41.43% Return On Equity
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; batch and intensified chromatography systems for smaller molecules applications, such as oligonucleotides, peptides, and insulin; and recombinant albumin based solutions. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of medications, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €4.31.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 66.82. Meaning, the purchaser of the share is investing €66.82 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 41.43%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 48.9% and 50.2%, respectively.
Volume
Today’s last reported volume for SARTORIUS STED BIO is 42465 which is 13.72% below its average volume of 49222.
Moving Average
SARTORIUS STED BIO’s value is below its 50-day moving average of €318.94 and way under its 200-day moving average of €331.90.
More news about SARTORIUS STED BIO.
